PMID- 38063264
OWN - NLM
STAT- MEDLINE
DCOM- 20240101
LR  - 20240123
IS  - 2045-7634 (Electronic)
IS  - 2045-7634 (Linking)
VI  - 12
IP  - 24
DP  - 2023 Dec
TI  - Addition of immune checkpoint inhibitors to chemotherapy versus chemotherapy 
      alone in patients with triple-negative breast cancer: A systematic review and 
      meta-analysis.
PG  - 21873-21884
LID - 10.1002/cam4.6760 [doi]
AB  - BACKGROUND: Triple-negative breast cancer (TNBC) is a relatively common malignant 
      tumor with high mortality rates. There are limited treatment options and current 
      therapy regimens often fall short of providing positive outcomes. The development 
      of immune checkpoint inhibitors (ICIs) have provided a vital treatment option 
      although efficacy has varied. Here, we review patient response to current TNBC 
      treatment with and without the addition of ICIs. METHODS: A systematic search of 
      PubMed, Cochrane, and EMBASE library databases was done to search eligible 
      studies published from their inception through April 3, 2022. The primary outcome 
      indicators used were progression-free survival (PFS), overall survival (OS), 
      pathological complete response rate (pCR) and objective remission rate (ORR), 
      while adverse events (AEs) were also analyzed. Publication bias and sensitivity 
      analyses and were performed to evaluate the quality of assessment. RESULTS: 
      Overall, the meta-analysis looked at seven randomized controlled trials (RCTs) 
      that included 4631 patients with TNBC. Results showed an improvement in PFS for 
      patients receiving ICI in addition to chemotherapy (CT) in both the 
      intent-to-treat (ITT) population and PD-L1 positive patients. Increased pCR rates 
      were observed in all patients irrespective of PD-L1 status as well as increased 
      ORR in the ITT which was more notable in PD-L1 positive subjects. While 
      significant improvement in OS was observed only in PD-L1 positive individuals, 
      the use of ICIs plus CT resulted in severe adverse reactions, specifically 
      immune-related. CONCLUSIONS: This study supports the increased efficacy of ICIs 
      in combination with CT compared to CT alone in patients with TNBC, with the most 
      notable benefit observed in PD-L1 positive patients. However, combination therapy 
      increases the risk of adverse reactions which warrants further investigation.
CI  - (c) 2023 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
FAU - Gao, Xin
AU  - Gao X
AD  - The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang 
      Provincial Hospital of Chinese Medicine), Hangzhou, Zhejiang, China.
FAU - Zhu, Ying
AU  - Zhu Y
AD  - The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang 
      Provincial Hospital of Chinese Medicine), Hangzhou, Zhejiang, China.
FAU - Wang, Peipei
AU  - Wang P
AUID- ORCID: 0000-0003-4389-4326
AD  - The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang 
      Provincial Hospital of Chinese Medicine), Hangzhou, Zhejiang, China.
FAU - Yu, Lulin
AU  - Yu L
AD  - The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang 
      Provincial Hospital of Chinese Medicine), Hangzhou, Zhejiang, China.
FAU - Ruan, Shanming
AU  - Ruan S
AUID- ORCID: 0000-0003-1061-5255
AD  - The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang 
      Provincial Hospital of Chinese Medicine), Hangzhou, Zhejiang, China.
FAU - Shen, Minhe
AU  - Shen M
AD  - The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang 
      Provincial Hospital of Chinese Medicine), Hangzhou, Zhejiang, China.
FAU - Zhang, Kai
AU  - Zhang K
AUID- ORCID: 0000-0002-8956-6187
AD  - The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang 
      Provincial Hospital of Chinese Medicine), Hangzhou, Zhejiang, China.
AD  - Anji Traditional Chinese Medical Hospital, Huzhou, Zhejiang, China.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
DEP - 20231208
PL  - United States
TA  - Cancer Med
JT  - Cancer medicine
JID - 101595310
RN  - 0 (Immune Checkpoint Inhibitors)
RN  - 0 (B7-H1 Antigen)
SB  - IM
MH  - Humans
MH  - *Immune Checkpoint Inhibitors/adverse effects
MH  - *Triple Negative Breast Neoplasms/drug therapy
MH  - B7-H1 Antigen
MH  - Combined Modality Therapy
MH  - Databases, Factual
MH  - Pathologic Complete Response
PMC - PMC10757081
OTO - NOTNLM
OT  - drug therapy
OT  - efficacy
OT  - immune checkpoint inhibitors
OT  - triple-negative breast cancer
COIS- The authors declare no conflict of interest.
EDAT- 2023/12/08 12:42
MHDA- 2024/01/02 11:46
PMCR- 2023/12/08
CRDT- 2023/12/08 07:48
PHST- 2023/09/05 00:00 [revised]
PHST- 2023/02/26 00:00 [received]
PHST- 2023/10/07 00:00 [accepted]
PHST- 2024/01/02 11:46 [medline]
PHST- 2023/12/08 12:42 [pubmed]
PHST- 2023/12/08 07:48 [entrez]
PHST- 2023/12/08 00:00 [pmc-release]
AID - CAM46760 [pii]
AID - 10.1002/cam4.6760 [doi]
PST - ppublish
SO  - Cancer Med. 2023 Dec;12(24):21873-21884. doi: 10.1002/cam4.6760. Epub 2023 Dec 8.